The U.S. Food and Drug Administration issued five warning letters to companies for selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Kennedy: Company Excited to Expand Generic Portfolio to Include Non-Respiratory Products
GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company’s proprietary NK cell engager (TriKE™) technology platform is pleased to announce the presentation…
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has initiated a series of proof of…
Action Follows Thorough Evaluation of Available Safety, Effectiveness, and Manufacturing Quality Information by FDA Career Scientists, Input from Independent Experts
The U.S. Food and Drug Administration approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation.
Slayback Pharma LLC issued the following announcement on Dec. 18.Slayback Pharma LLC announced today that it has received final approval for its Abbreviated New Drug Application (ANDA) for Merzee (norethindrone…
The U.S. Food and Drug Administration approved the Osseoanchored Prostheses for the Rehabilitation of Amputees (OPRA) Implant System
Occlutech, a privately-held company, announced today that the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its first-in-class, implantable Atrial Flow Regulator (AFR)…
The U.S. Food and Drug Administration approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer.
Oral XPOVIO Now Available as a Treatment Option for Patients with Multiple Myeloma As Early as First Relapse; Significantly Expands Addressable Patient Population
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that…
Large, Randomized Controlled ADVENT Trial Designed to Establish New Gold Standard for AF Ablation
Alteration intended to eliminate alpha-gal sugar on surface of pigs’ cells
The National Safety Council applauds today’s formal recommendation of the Pfizer COVID-19 vaccine and the CDC recommendations that prioritize distributing the vaccine first to healthcare personnel and long-term care facility…
Action Follows Thorough Evaluation of Available Safety, Effectiveness, and Manufacturing Quality Information by FDA Career Scientists, Input from Independent Experts
The following is attributed to FDA Commissioner Stephen M. Hahn, M.D., and Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research.
The following is attributed to FDA Commissioner Stephen M. Hahn, M.D.
Test system is authorized for at-home sample collection with laboratory test processing
Verantos today announced it has received a grant award from the U.S. Food and Drug Administration (FDA) to implement a multi-year advanced real-world evidence (RWE) study.
Novel radial artery occlusion device removes the guesswork from achieving Patent Hemostasis
Dr. David Berger of Wholistic Pediatrics & Family Care presents to the FDA’s vaccine approval committee regarding alleviating public concerns and hesitations.
Volta Medical, a pioneering French-based HealthTech startup is pleased to announce that it has obtained FDA clearance for its revolutionary VX1 AI (artificial intelligence) software.
The COVID-19 pandemic has resulted in an immense number of deaths, disrupted economies worldwide and is a public health emergency.
Sign-up for the Weekly Newsletter from FDA Reporter.
